超血症的治疗标准是高血症
Biff F Palmer1, Deborah J Clegg2
1Professor of Internal Medicine, Department of Medicine, Division of Nephrology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
概括
高血症,或高水平,需要及时管理. 对于急性和慢性病例,治疗策略各不相同,重点是立即稳定,将转移到细胞中,并减少整体体质.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 内部医学 内部医学
- 心脏病学 心脏病学
背景情况:
- 高血是临床实践中经常出现的电解质失衡.
- 严重程度和风险取决于增加的原因和速度.
- 急性高血症带来危及生命的风险,需要立即介入.
研究的目的:
- 概述急性和慢性高血症的管理策略.
- 讨论药物和饮食干预措施的作用.
- 强调在特定患者群体中氨酸- ангиотензин- алдостерон抑制剂的重要性.
主要方法:
- 最初的治疗侧重于心脏膜稳定.
- 随后的步骤包括将转移到细胞中.
- 长期管理包括解决潜在原因和优化疗法.
主要成果:
- 慢性高血症虽然不那么严重,但与增加的发病率和死亡率有关.
- 饮食中的限制正在重新评估,更倾向于关注非植物来源.
- 由于其已被证明的益处,不建议停止使用氨酸- ангиотензин-阿尔多斯特抑制剂.
结论:
- 超血症的管理需要基于敏度和患者因素的量身定制方法.
- 保守措施,结合剂和SGLT2抑制剂有助于治疗慢性高血症.
- 保持像RAAS抑制剂这样有益的疗法对于患者的治疗结果至关重要.
相关概念视频
Antihypertensive Drugs: Potassium-Sparing Diuretics
545
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
545
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
994
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
994
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.4K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.4K
Heart Failure Drugs: Inotropic Agents
586
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
586
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
743
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
743
Antiepileptic Drugs: Potassium Channel Activators
183
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
183


